Journey Medical (DERM) Expected to Announce Earnings on Wednesday

Journey Medical (NASDAQ:DERM) is expected to release its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect Journey Medical to post earnings of ($0.07) per share and revenue of $15.4730 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Journey Medical (NASDAQ:DERM) last posted its earnings results on Wednesday, March 25th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The firm had revenue of $16.08 million for the quarter, compared to analyst estimates of $18.86 million. Journey Medical had a negative net margin of 18.48% and a negative return on equity of 46.40%. On average, analysts expect Journey Medical to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Journey Medical Stock Up 1.2%

Shares of NASDAQ DERM opened at $5.18 on Wednesday. The company has a market capitalization of $141.57 million, a P/E ratio of -11.02 and a beta of 1.03. Journey Medical has a 52-week low of $4.31 and a 52-week high of $9.56. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.53 and a current ratio of 1.79. The company’s 50 day moving average price is $6.28 and its 200-day moving average price is $7.41.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Jump Financial LLC lifted its position in shares of Journey Medical by 46.1% during the 4th quarter. Jump Financial LLC now owns 20,183 shares of the company’s stock valued at $156,000 after acquiring an additional 6,373 shares during the period. Bank of America Corp DE lifted its position in shares of Journey Medical by 421.0% during the 3rd quarter. Bank of America Corp DE now owns 21,537 shares of the company’s stock valued at $153,000 after acquiring an additional 17,403 shares during the period. Marshall Wace LLP acquired a new position in shares of Journey Medical during the 4th quarter valued at $150,000. Occudo Quantitative Strategies LP lifted its position in shares of Journey Medical by 22.3% during the 4th quarter. Occudo Quantitative Strategies LP now owns 18,913 shares of the company’s stock valued at $146,000 after acquiring an additional 3,443 shares during the period. Finally, Wells Fargo & Company MN lifted its position in shares of Journey Medical by 109.1% during the 4th quarter. Wells Fargo & Company MN now owns 15,748 shares of the company’s stock valued at $121,000 after acquiring an additional 8,215 shares during the period. Institutional investors and hedge funds own 7.25% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DERM. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Journey Medical in a research report on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Journey Medical in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Journey Medical currently has an average rating of “Hold” and an average price target of $13.00.

Journey Medical Company Profile

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.